IRIS
PELLEGRINO, BENEDETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 538
NA - Nord America 455
AS - Asia 62
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.057
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 450
IE - Irlanda 221
SE - Svezia 118
IT - Italia 72
AT - Austria 62
CN - Cina 52
DE - Germania 32
FI - Finlandia 10
BE - Belgio 8
CA - Canada 5
IN - India 4
ES - Italia 3
GB - Regno Unito 3
PL - Polonia 3
TR - Turchia 3
A1 - Anonimo 2
CZ - Repubblica Ceca 2
FR - Francia 2
NL - Olanda 2
HK - Hong Kong 1
IR - Iran 1
PH - Filippine 1
Totale 1.057
Salva come PNG Salva come JPEG
Città #
Dublin 221
Chandler 179
Vienna 52
Beijing 26
Ann Arbor 23
Princeton 22
Bremen 21
Boardman 19
Ashburn 13
Dearborn 13
Des Moines 13
Helsinki 10
Ardea 8
Milan 8
Wilmington 8
Brussels 6
Falls Church 5
Rio Saliceto 5
Nanjing 4
Rome 4
Fairfield 3
Hanover 3
Kunming 3
Montreal 3
Nanchang 3
Parma 3
Woodbridge 3
Bastia umbra 2
Bologna 2
Brooklyn 2
Capriate San Gervasio 2
Hebei 2
Izmir 2
Jinan 2
Madrid 2
Menlo Park 2
Pavia 2
Seattle 2
Shenzhen 2
Stockholm 2
Trento 2
Andover 1
Ardabil 1
Augusta 1
Borås 1
Brno 1
Corno di Rosazzo 1
Edinburgh 1
Fremont 1
Gambettola 1
Grafing 1
Guangzhou 1
Hangzhou 1
Hefei 1
Hong Kong 1
Huizen 1
Imola 1
Kocaeli 1
Leuven 1
London 1
Los Angeles 1
Manila 1
Molenbeek-Saint-Jean 1
Nanning 1
Naples 1
Piacenza 1
Prague 1
Redmond 1
Reggio Emilia 1
Rockville 1
San Francisco 1
Taglio Di Po 1
Tappahannock 1
Tianjin 1
Zhengzhou 1
Totale 743
Salva come PNG Salva come JPEG
Nome #
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 69
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 65
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 55
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 53
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 52
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 52
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 51
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 50
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 46
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 44
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 44
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 43
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 41
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 40
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification 39
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 37
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors 34
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 34
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 33
A review of immune checkpoint blockade in breast cancer 33
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 32
My best choice after a round trip from illness 32
A narrative review of the principal glucocorticoids employed in cancer 28
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 25
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 23
The Innate Immune Microenvironment in Metastatic Breast Cancer 19
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? 15
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors 7
RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test 4
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 3
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 3
Totale 1.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.806
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.806
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20199 0 0 0 0 4 0 0 0 2 0 2 1
2019/202086 7 1 0 1 6 11 5 2 2 40 10 1
2020/202189 2 8 1 5 6 14 15 12 4 6 13 3
2021/202296 1 2 6 7 5 6 7 5 2 8 0 47
2022/2023728 49 66 33 48 70 71 17 52 254 6 45 17
2023/202490 17 31 9 6 27 0 0 0 0 0 0 0
Totale 1.106